On July 16, RenBio’s President and Chief Scientific Officer, Dr. Rachel Liberatore, presented at the Obesity Conference 2026 | Weight Loss Drug Development Summit in Boston, where she delivered a presentation entitled, “Ultra Long-lasting, DNA-Based Delivery of Incretin Receptor Agonists.”
Dr. Liberatore highlighted RenBio’s proprietary MYO Technology™ platform and its potential to enable durable, DNA-based delivery of incretin receptor agonists for the treatment of obesity and other metabolic diseases. The presentation showcased the promise of ultra long-lasting DNA medicines designed to provide sustained therapeutic benefit from a single administration, with the potential to improve treatment durability, adherence, and long-term disease management.
View Dr. Liberatore’s presentation here.